-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec's content team On September 8, 2021, Sanofi announced that it has reached an approximately US$1.
9 billion acquisition agreement with Kadmon Holdings
.
The acquisition will add Kadmon's small molecule therapy Rezurock (belumosudil) to its transplant portfolio
.
It is worth mentioning that the small molecule therapy was approved by the FDA just 2 months ago
.
Kadmon is a biomedical company dedicated to discovering, developing and providing transformative therapies for unmet medical needs.
The pipeline includes candidate products for immune and fibrotic diseases and immuno-oncology therapies
.
In July 2021, the US FDA approved the company's Rezurock for the treatment of chronic graft-versus-host disease (cGVHD) children (12 years and older) and adult patients.
These patients have already received two pre-systemic treatments
.
Rezurock is the first approved small molecule therapy to inhibit Rho-related coiled-coil kinase 2 (ROCK2)
.
Kadmon is also developing Rezurock for the treatment of diffuse skin systemic sclerosis, and an open-label Phase 2 clinical trial is currently underway
.
▲Illustration of Belumosudil's mechanism of action (picture source: Reference [2]) Kadmon President and CEO Dr.
Harlan Waksal said: "We are very pleased that Sanofi recognizes the value of Rezurock and the deep potential of our pipeline
.
By leveraging Sanofi's global resources and long-term expertise in the development and promotion of innovative drugs, Rezurock can achieve global access faster
.
"Reference: [1] Sanofi to acquire Kadmon to further strengthen growth of transplant business.
Retrieved 2021-09-08, from https:// /en/Sanofi-to-acquire-Kadmon-to-further-strengthen-growth-of-transplant-business.
html[2] Kadmon Corporate Presentation.
Retrieved July 16, 2021, from https://investors.
kadmon.
com/ static-files/a9d862ce-b6cb-4cd6-b368-6182271b3d58 Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
9 billion acquisition agreement with Kadmon Holdings
.
The acquisition will add Kadmon's small molecule therapy Rezurock (belumosudil) to its transplant portfolio
.
It is worth mentioning that the small molecule therapy was approved by the FDA just 2 months ago
.
Kadmon is a biomedical company dedicated to discovering, developing and providing transformative therapies for unmet medical needs.
The pipeline includes candidate products for immune and fibrotic diseases and immuno-oncology therapies
.
In July 2021, the US FDA approved the company's Rezurock for the treatment of chronic graft-versus-host disease (cGVHD) children (12 years and older) and adult patients.
These patients have already received two pre-systemic treatments
.
Rezurock is the first approved small molecule therapy to inhibit Rho-related coiled-coil kinase 2 (ROCK2)
.
Kadmon is also developing Rezurock for the treatment of diffuse skin systemic sclerosis, and an open-label Phase 2 clinical trial is currently underway
.
▲Illustration of Belumosudil's mechanism of action (picture source: Reference [2]) Kadmon President and CEO Dr.
Harlan Waksal said: "We are very pleased that Sanofi recognizes the value of Rezurock and the deep potential of our pipeline
.
By leveraging Sanofi's global resources and long-term expertise in the development and promotion of innovative drugs, Rezurock can achieve global access faster
.
"Reference: [1] Sanofi to acquire Kadmon to further strengthen growth of transplant business.
Retrieved 2021-09-08, from https:// /en/Sanofi-to-acquire-Kadmon-to-further-strengthen-growth-of-transplant-business.
html[2] Kadmon Corporate Presentation.
Retrieved July 16, 2021, from https://investors.
kadmon.
com/ static-files/a9d862ce-b6cb-4cd6-b368-6182271b3d58 Note: This article aims to introduce the progress of medical and health research, not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
